136 related articles for article (PubMed ID: 35049171)
1. Ranibizumab and conbercept for treating wet age-related macular degeneration in China: A systematic review and meta-analysis.
Pengfei J; Hanyu T; Qinghua P
Medicine (Baltimore); 2021 Dec; 100(48):e27774. PubMed ID: 35049171
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis.
Wang L; Zhang C; Hua R
Drug Des Devel Ther; 2018; 12():3625-3633. PubMed ID: 30464394
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Efficacy and Safety between Conbercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: A Meta-Analysis of Randomized Controlled Trials.
Wang X; Yu C; Yang J; Liu Y; Xu Y; Li W
Ophthalmic Res; 2022; 65(2):140-151. PubMed ID: 34583363
[TBL] [Abstract][Full Text] [Related]
4. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study.
Cui J; Sun D; Lu H; Dai R; Xing L; Dong H; Wang L; Wei D; Jiang B; Jiao Y; Jablonski MM; Charles S; Gu W; Chen H
Eye (Lond); 2018 Feb; 32(2):391-399. PubMed ID: 28937147
[TBL] [Abstract][Full Text] [Related]
5. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
6. Conbercept for patients with age-related macular degeneration: a systematic review.
Zhang J; Liang Y; Xie J; Li D; Hu Q; Li X; Zheng W; He R
BMC Ophthalmol; 2018 Jun; 18(1):142. PubMed ID: 29902977
[TBL] [Abstract][Full Text] [Related]
7. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
8. SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR BEFORE AND AFTER INTRAVITREAL INJECTION OF RANIBIZUMAB OR CONBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Jin E; Bai Y; Luo L; Huang L; Zhu X; Ding X; Qi H; Zhao M
Retina; 2017 May; 37(5):971-977. PubMed ID: 27617537
[TBL] [Abstract][Full Text] [Related]
9. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
10. The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization.
Chen C; Yan M; Huang Z; Song YP
Curr Eye Res; 2020 Nov; 45(11):1415-1421. PubMed ID: 32191134
[No Abstract] [Full Text] [Related]
11. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis.
Cui C; Lu H
Clin Interv Aging; 2018; 13():51-62. PubMed ID: 29343949
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
[TBL] [Abstract][Full Text] [Related]
13. One-Year Outcomes of Intravitreal Conbercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration.
Li X; Zhang Y; Zhang Z; Xu Y; Zhang M
Ophthalmic Res; 2019; 62(2):93-100. PubMed ID: 31121579
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.
Xu Y; Rong A; Xu W; Niu Y; Wang Z
BMC Ophthalmol; 2017 Aug; 17(1):158. PubMed ID: 28841827
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis.
Su Y; Wu J; Gu Y
Photodiagnosis Photodyn Ther; 2018 Jun; 22():263-273. PubMed ID: 29753123
[TBL] [Abstract][Full Text] [Related]
16. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
Inan S; Baysal Z; Inan UU
Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
[No Abstract] [Full Text] [Related]
18. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
[TBL] [Abstract][Full Text] [Related]
19. One-year outcomes of the Polish treatment program for the wet form of age-related macular degeneration using intravitreal therapy.
Figurska M; Matysik-Wożniak A; Adamiec-Mroczek J; Dolar-Szczasny J; Misiuk-Hojło M; Teper S; Święch-Zubilewicz A; Ulińska M; Rejdak R; Rękas M
Eur J Ophthalmol; 2020 May; 30(3):586-594. PubMed ID: 32347762
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
Narayan DS; Muecke J
Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]